358 related articles for article (PubMed ID: 26538546)
1. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
5. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
[TBL] [Abstract][Full Text] [Related]
6. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology.
Koschinsky ML; Boffa MB
Atherosclerosis; 2022 May; 349():92-100. PubMed ID: 35606081
[TBL] [Abstract][Full Text] [Related]
7. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
Yeang C; Cotter B; Tsimikas S
Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
Scipione CA; Koschinsky ML; Boffa MB
Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
10. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung MY; Tsimikas S
Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
Vuorio A; Watts GF; Kovanen PT
Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
[TBL] [Abstract][Full Text] [Related]
12. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.
Yeang C; Wilkinson MJ; Tsimikas S
Curr Opin Cardiol; 2016 Jul; 31(4):440-50. PubMed ID: 27205885
[TBL] [Abstract][Full Text] [Related]
14. Oxidized phospholipids and lipoprotein-associated phospholipase A
Tselepis AD
J Biomed Res; 2018 Jan; 31(1):13-22. PubMed ID: 27346583
[TBL] [Abstract][Full Text] [Related]
15. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.
Capoulade R; Chan KL; Yeang C; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Mahmut A; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
J Am Coll Cardiol; 2015 Sep; 66(11):1236-1246. PubMed ID: 26361154
[TBL] [Abstract][Full Text] [Related]
16. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.
Boffa MB; Marar TT; Yeang C; Viney NJ; Xia S; Witztum JL; Koschinsky ML; Tsimikas S
J Lipid Res; 2019 Dec; 60(12):2082-2089. PubMed ID: 31551368
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein (a): When to Measure and How to Treat?
Rhainds D; Brodeur MR; Tardif JC
Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
[TBL] [Abstract][Full Text] [Related]
18. Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.
Kamstrup PR; Hung MY; Witztum JL; Tsimikas S; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1570-1578. PubMed ID: 28572160
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a)-antisense therapy.
Vogt A
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384
[TBL] [Abstract][Full Text] [Related]
20. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
Vasquez N; Joshi PH
Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
